HOME >> MEDICINE >> NEWS
Future blood tests may use tiny bar-codes to speed disease diagnosis

Analyzing a blood sample for the presence of disease markers, either in a doctor's office or on the battlefield, could soon become as quick and easy as scanning the bar-code of a grocery item. Using nanotechnology, researchers at Northwestern University have developed a way to label tiny disease markers in blood with unique DNA tags, which they call bio-bar-codes. The tags can then be scanned by an instrument to identify diseases ranging from cancer to Alzheimer's, or identify exposure to bioterror agents such as anthrax and smallpox, they say.

Details about the analytical test, which appears promising in experimental studies, are scheduled to appear in the May 19 print issue of the Journal of the American Chemical Society, a peer-reviewed publication of the American Chemical Society, the world's largest scientific society. The study was published online today (April 27) on the journal's Web site.

"This test has the potential to completely revolutionize medical diagnostics," says Chad A. Mirkin, Ph.D., head of the study and director of Northwestern's Institute for Nanotechnology, located in Evanston, Ill. He says that the test will bring efficient, high-tech DNA diagnostics to unprecedented settings, including the battlefield and Third World villages, as well as hospitals and the home.

The test is easier, faster, more accurate and less expensive than polymerase chain reaction (PCR), which is currently used to detect and quantify DNA samples, he says. The new test, called bio-bar-code amplification (BCA), could be ready for marketing in as little as one year, Mirkin says.

Unlike conventional tests that require one or more vials of blood, the new test allows a single drop of blood to paint a patient's comprehensive disease profile in about the same amount of time it takes for a routine doctor's visit.

The test is based on a set of chemical probes that are used to tag disease markers. If one is trying to detect exposure
'"/>

Contact: Michael Bernstein
m_bernstein@acs.org
202-872-6042
American Chemical Society
27-Apr-2004


Page: 1 2

Related medicine news :

1. Future of clinical medicine research is at risk, warns professor
2. NYU Child Study Center to launch Healthy Kids, Happy Futures
3. Creators of robot for the elderly to demonstrate technologies at Future of Aging Services Conference
4. Cancer markers news backgrounder: Future of cancer diagnosis, treatment lies in tumor barcode
5. Future medical leaders have shorter futures, study says
6. Wound healing gel wins Medical Futures award
7. GPs Of The Future Will Be Information Specialists
8. Future Chlamydia Screening Should Take Account Of Possible Disadvantages For Women
9. New Research Identifies Outcomes And Future Trends Based On Past Behaviors, Experience
10. Future Workers Will Receive MSAs
11. Beyond Pharmaceuticals: Business And Academic Leaders Forecast The Future Of "Combinatorial Chemistry"

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Future blood tests may use tiny bar codes speed disease diagnosis

(Date:11/27/2014)... November 27, 2014 Now that Thanksgiving ... has officially launched, Emassagechair.com has announced its ... Discount Event. , Negotiating on behalf of their ... massage chair brands, Emassagechair.com has generated significant buzz in ... and biggest discounts yet. , Shoppers are excited for ...
(Date:11/27/2014)... OXNARD, CA (PRWEB) November 27, 2014 ... All-on-4™ dental implants procedure will help one person ... rehabilitation. , Dr. Saj Jivraj and Dr. Mamaly Reshad ... Woodland Hills, Calif., have launched a website devoted to ... A section of the website would be devoted to ...
(Date:11/27/2014)... Washington, DC (PRWEB) November 27, 2014 “Wekho” ... which features the latest and coolest mobile applications on the ... expert and host of NewsWatch, conducted the app review ... follow locations instead of people. , An interesting new way ... for iOS and Android devices. It’s called Wekho and ...
(Date:11/27/2014)... Developers and plugin specialist of Final Cut Pro ... FCPX to the next level. , “ProPip allows users to ... of a mouse,” said Christina Austin, CEO of Pixel Film ... appreciate.” , With ProPip users can show off their ... ProPip is great for commentaries, news casting, and more. PROPIP™ ...
(Date:11/27/2014)... November 27, 2014 This is ... Global Insulin industry. For an overview analysis, the ... application, industry chain structure, industry overview, policy analysis, ... Insulin industry covers information on policy, plans ... cost structure and much more. , ...
Breaking Medicine News(10 mins):Health News:Emassagechair.com is Excited to Announce Their Biggest Discount Event of the Year, Starting the Day After Thanksgiving and Lasting Through The Holiday Weekend. 2Health News:Emassagechair.com is Excited to Announce Their Biggest Discount Event of the Year, Starting the Day After Thanksgiving and Lasting Through The Holiday Weekend. 3Health News:Emassagechair.com is Excited to Announce Their Biggest Discount Event of the Year, Starting the Day After Thanksgiving and Lasting Through The Holiday Weekend. 4Health News:World-Renowned Oxnard All-on-4™ Dental Implants Experts to Give Away Full Mouth Rehabilitation Annually 2Health News:World-Renowned Oxnard All-on-4™ Dental Implants Experts to Give Away Full Mouth Rehabilitation Annually 3Health News:World-Renowned Oxnard All-on-4™ Dental Implants Experts to Give Away Full Mouth Rehabilitation Annually 4Health News:World-Renowned Oxnard All-on-4™ Dental Implants Experts to Give Away Full Mouth Rehabilitation Annually 5Health News:A New Geolocation Mobile Application and was Featured on NewsWatch Television on October 30, 2014 2Health News:Pixel Film Studios released ProPip plugin Exclusively for Final Cut Pro X 2Health News:Pixel Film Studios released ProPip plugin Exclusively for Final Cut Pro X 3Health News:Insulin Industry Analysis (Supply, Consumption) for China, America, Korea, France & Japan Research Now at ReportsnReports 2Health News:Insulin Industry Analysis (Supply, Consumption) for China, America, Korea, France & Japan Research Now at ReportsnReports 3
(Date:11/26/2014)... Nov. 25, 2014  Unilife Corporation (NASDAQ: UNIS, ASX: ... delivery systems, today announced that its Chairman and CEO, ... the Piper Jaffray 26th Annual Healthcare Conference at the ... Tuesday, December 2, 2014. The conference ... "live" listen only Webcast. To listen, please go to: ...
(Date:11/26/2014)... and LONDON , Nov. 25, ... AstraZeneca (NYSE: AZN ) today announced that AMAGINE-2 ... doses of brodalumab in more than 1,800 patients with moderate-to-severe ... Stelara ® (ustekinumab) and placebo at week 12. Brodalumab ... analysis group were each shown to be superior to Stelara ...
(Date:11/26/2014)... , Nov. 25, 2014 Halozyme Therapeutics, Inc. (NASDAQ: ... Jaffray Healthcare Conference in New York ... PDT . Dr. Helen Torley , President and ... The presentation will be webcast through the "Investors" section of ... will be made available for 90 days following the event. ...
Breaking Medicine Technology:Unilife to Present at the Piper Jaffray 26th Annual Healthcare Conference on December 2nd 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 3Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 4Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 5Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 6Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 7Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 8Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 9Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 10Halozyme Therapeutics To Present At The Piper Jaffray Healthcare Conference 2
Cached News: